These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
247 related articles for article (PubMed ID: 36879416)
1. Oncolytic Virus-Driven Biotherapies from Bench to Bedside. Duan S; Wang S; Qiao L; Yu X; Wang N; Chen L; Zhang X; Zhao X; Liu H; Wang T; Wu Y; Li N; Liu F Small; 2023 Jun; 19(23):e2206948. PubMed ID: 36879416 [TBL] [Abstract][Full Text] [Related]
2. Emerging systemic delivery strategies of oncolytic viruses: A key step toward cancer immunotherapy. Ban W; Guan J; Huang H; He Z; Sun M; Liu F; Sun J Nano Res; 2022; 15(5):4137-4153. PubMed ID: 35194488 [TBL] [Abstract][Full Text] [Related]
3. Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy. Wang X; Shen Y; Wan X; Hu X; Cai WQ; Wu Z; Xin Q; Liu X; Gui J; Xin HY; Xin HW J Transl Med; 2023 Jul; 21(1):500. PubMed ID: 37491263 [TBL] [Abstract][Full Text] [Related]
4. Development of oncolytic virotherapy: from genetic modification to combination therapy. Lan Q; Xia S; Wang Q; Xu W; Huang H; Jiang S; Lu L Front Med; 2020 Apr; 14(2):160-184. PubMed ID: 32146606 [TBL] [Abstract][Full Text] [Related]
5. Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas. Zeng J; Li X; Sander M; Zhang H; Yan G; Lin Y Front Immunol; 2021; 12():721830. PubMed ID: 34675919 [TBL] [Abstract][Full Text] [Related]
8. Oncolytic vaccinia virus and cancer immunotherapy. Xu L; Sun H; Lemoine NR; Xuan Y; Wang P Front Immunol; 2023; 14():1324744. PubMed ID: 38283361 [TBL] [Abstract][Full Text] [Related]
10. Oncolytic Viruses as an Adjunct to Immune Checkpoint Inhibition. Ripp J; Hentzen S; Saeed A Front Biosci (Landmark Ed); 2022 May; 27(5):151. PubMed ID: 35638418 [TBL] [Abstract][Full Text] [Related]
11. Achieving systemic delivery of oncolytic viruses. Hill C; Carlisle R Expert Opin Drug Deliv; 2019 Jun; 16(6):607-620. PubMed ID: 31144549 [TBL] [Abstract][Full Text] [Related]
12. Determinants of the efficacy of viro-immunotherapy: A review. de Graaf JF; Huberts M; Fouchier RAM; van den Hoogen BG Cytokine Growth Factor Rev; 2020 Dec; 56():124-132. PubMed ID: 32919831 [TBL] [Abstract][Full Text] [Related]
13. Clinical landscape of oncolytic virus research in 2020. Macedo N; Miller DM; Haq R; Kaufman HL J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33046622 [TBL] [Abstract][Full Text] [Related]
14. Combinatorial Approaches for Cancer Treatment Using Oncolytic Viruses: Projecting the Perspectives through Clinical Trials Outcomes. Malogolovkin A; Gasanov N; Egorov A; Weener M; Ivanov R; Karabelsky A Viruses; 2021 Jun; 13(7):. PubMed ID: 34209981 [TBL] [Abstract][Full Text] [Related]
15. A call to arms: using RNAi screening to improve oncolytic viral therapy. Mahoney DJ; Stojdl DF Cytokine Growth Factor Rev; 2010; 21(2-3):161-7. PubMed ID: 20207578 [TBL] [Abstract][Full Text] [Related]
16. Oncolytic virotherapy as promising immunotherapy against cancer: mechanisms of resistance to oncolytic viruses. Goradel NH; Alizadeh A; Hosseinzadeh S; Taghipour M; Ghesmati Z; Arashkia A; Negahdari B Future Oncol; 2022 Jan; 18(2):245-259. PubMed ID: 34821517 [TBL] [Abstract][Full Text] [Related]
17. Updates to the antitumor mechanism of oncolytic virus. Bai Y; Hui P; Du X; Su X Thorac Cancer; 2019 May; 10(5):1031-1035. PubMed ID: 30900824 [TBL] [Abstract][Full Text] [Related]